CAR-T Therapy in HIV:Pioneering Advances and Navigating Challenges  

作　　者：Xiao Wang Jianyang Liu Feike Hao Tatchapon Ajavavarakula Xuanling Shi 

机构地区：[1]School of Basic Medical Sciences,Tsinghua University,Beijing 100084,China [2]Tsingmed Therapeutic Technology Co.,Ltd.,Beijing 100084,China [3]School of Life Sciences,Tsinghua University,Beijing 100084,China

出　　处：《Infectious Diseases & Immunity》2024年第4期194-205,共12页感染性疾病与免疫（英文）

基　　金：supported by the National Key Research and Development Program of China(2022YFC2604100);the National Science and Technology Major Project(2018ZX10302104-003).

摘　　要：Chimeric antigen receptor T(CAR-T)cell therapy,renowned for its successes in cancer treatment,is now entering the field of human immunodeficiency virus(HIV)therapy,presenting both opportunities and challenges.With the emergence of broadly neutralizing antibodies,multi-target CARs,and T cell receptor-like antibodies aimed at increasing specificity in targeting HIV reservoirs,CAR-T therapy is synergizing with other cutting-edge treatments,including gene-editing technologies,therapeutic vaccines,and latency-reversing agents,in pursuit of a potential functional cure.In this review,we delve into the role of CAR-T therapy in HIV treatment,highlighting its potential to overcome clinical obstacles.We discuss advancements in targeting strategies within CAR constructs and the intricate regulation of T cell proliferation and chemotaxis.Moreover,we explore the use of diverse immune cells,such as gamma-delta T cells and natural killer cells.We review advanced biotechnologies,manufacturing innovations,viral mechanisms,and immune microenvironments.We also discuss the current research landscape and potential future applications of CAR-T therapy against HIV,which remains a critical global health challenge.

关 键 词：HIV AIDS CAR-T cell therapy functional cure immune cells 

分 类 号：R512.91[医药卫生—内科学]